S2Medical AB (publ)
STO:S2M
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0085
0.1295
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
S2Medical AB (publ)
Total Equity
S2Medical AB (publ)
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Total Equity
kr10.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Total Equity
kr251.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Total Equity
kr2.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
29%
|
CAGR 10-Years
28%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Total Equity
kr3.1B
|
CAGR 3-Years
237%
|
CAGR 5-Years
185%
|
CAGR 10-Years
75%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Total Equity
kr353.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Total Equity
€667.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S2Medical AB (publ)
Glance View
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
See Also
What is S2Medical AB (publ)'s Total Equity?
Total Equity
10.1m
SEK
Based on the financial report for Jun 30, 2024, S2Medical AB (publ)'s Total Equity amounts to 10.1m SEK.
What is S2Medical AB (publ)'s Total Equity growth rate?
Total Equity CAGR 5Y
-22%
Over the last year, the Total Equity growth was -37%. The average annual Total Equity growth rates for S2Medical AB (publ) have been -25% over the past three years , -22% over the past five years .
You don't have any saved screeners yet
